Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density.

ABSTRACT:

Context

In the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly - Pivotal Fracture Trial (HORIZON-PFT), zoledronic acid (ZOL) 5 mg significantly reduced fracture risk.

Objective

The aim of the study was to identify factors associated with greater efficacy during ZOL 5 mg treatment.

Design, setting, and patients

We conducted a subgroup analysis (preplanned and post hoc) of a multicenter, double-blind, placebo-controlled, 36-month trial in 7765 women with postmenopausal osteoporosis.

Intervention

A single infusion of ZOL 5 mg or placebo was administered at baseline, 12, and 24 months.

Main outcome measures

Primary endpoints were new vertebral fracture and hip fracture. Secondary endpoints were nonvertebral fracture and change in femor

SUBMITTER: Eastell R 

PROVIDER: S-EPMC5101059 | biostudies-literature | 2009 Sep

REPOSITORIES: biostudies-literature